BUSINESS
Enhertu Earns FDA’s Priority Tag for Gastric Cancer, Decision Due in Q1 2021
Daiichi Sankyo and AstraZeneca said on October 28 that the US FDA has accepted for priority review their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) for an additional indication of certain patients with gastric cancer.Their application seeks the drug’s label…
To read the full story
Related Article
- Enhertu Gets FDA Nod for Gastric Cancer, 2nd Indication in US
January 19, 2021
- Enhertu Gets US FDA’s Orphan Status for Gastric Cancer
May 25, 2020
BUSINESS
- GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
- Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
July 3, 2026
- PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
July 3, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





